Loading
Aldeyra Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 05 Jun 2026.
Aldeyra Therapeutics, Inc.: what insiders have been doing
Aldeyra Therapeutics, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 3 filings came from 3 insiders.
No insider sold shares on the market over the period. Instead, the filings list 3 purchases totalling €452k, made by 3 insiders. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. On the buying side, the filings list 2 senior executives and 1 chief executive among the declarants. At €360k, the purchase published on 5 June 2026 by Brady Todd C is the largest of the period (0.34% of market cap).
The data flag 1 purchase as part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster. The last insider purchase was made public on 5 June 2026, 135 days ago. The median gap between a trade and its publication by SEC (Form 4) is 1 day. Section 16 rules allow two business days to file each Form 4.
For context, the typical company on the same exchange (median of 5,816 companies) published 19 filings over the same period, against 3 filings here. Since 2021, the database holds 19 purchases and 9 sales by insiders of the company.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
38
Thresholds
n/a
Buy Volume
€22M
19 ops. · all time
Sell Volume
€9M
9 ops. · all time
Who traded when
BuySaleMichael Alfieri2 buys
Perceptive Advisors LLC1 sale
Richard Douglas1 buy
Stephen Machatha1 sale
Todd C. Brady1 buy
Since the insiders bought
- -57.6%Entry US$1.74 · Close 15 Oct 2026 US$0.74
- -8.1%Entry US$2.23 · Close at T+90 US$2.05
- +8.3%Entry US$1.81 · Close at T+90 US$1.96
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Aldeyra Therapeutics, Inc. Strong Buy (bullish), based on 5 analysts. Average price target: US$6.60.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.29
Analyst consensus
5 analystsStrong buy
US$2.00Target US$6.60(+412%)US$13.00
Income statement
EBITDA-US$31.7M
Net income-US$33.8M0.0% margin
Valuation
PER (forward)-4.7x
P/Book2.1x
Beta1.19
Balance sheet & cash
Market capUS$77.8M
Total debtUS$15.5M
Free Cash Flow-US$33.3M
Debt / Equity0%
Profitability & ownership
ROE-49.5%
ROA-22.7%
% insiders3.6%
% institutions61.5%
Last declaration on 5 June 2026
Declarations38 total
250,000 shares@ US$1.67380.34% mcap44.5% of flowCommon StockSEC:0001193125-26-259637:0
Canonical exit: 1 Sept 2026 (T+90)
70,000 shares@ US$1.40100.0% of flowCommon StockSEC:0001193125-26-117675:0
Canonical exit: 17 Jun 2026 (T+90)
5,000 shares@ US$1.4235.2% of flowCommon StockSEC:0001193125-26-116247:0
Canonical exit: 16 Jun 2026 (T+90)
2,500 shares@ US$5.3064.8% of flowCommon StockSEC:0000950170-25-109391:0
Canonical exit: 11 Nov 2025 (T+90)
22,073 shares@ US$5.151738.0% of flowCommon StockSEC:0000950170-25-108210:0
3,400,000 shares@ US$1.4214.9% of flowCommon StockSEC:0001062993-25-007163:0
413 shares@ US$12.81100.0% of flowCommon StockSEC:0000950170-24-116048:0
Canonical exit: 1 Aug 2021 (T+90)
10,834 shares@ US$4.736353.3% of flowCommon StockSEC:0000950170-24-097070:0
16,041 shares@ US$4.736327.0% of flowCommon StockSEC:0000950170-24-097071:0
11,537 shares@ US$3.16413.0% of flowCommon StockSEC:0000950170-24-045113:0
140,281 shares@ US$4.672.1% of flowCommon StockSEC:0001062993-24-008171:0
Canonical exit: 3 Jul 2024 (T+90)
8,374 shares@ US$3.250.1% of flowCommon StockSEC:0001062993-24-007959:0
Canonical exit: 30 Jun 2024 (T+90)
18,231 shares@ US$3.406422.0% of flowCommon StockSEC:0000950170-24-030311:0
97,914 shares@ US$3.273536.2% of flowCommon StockSEC:0000950170-24-030309:0
13,201 shares@ US$3.406446.7% of flowCommon StockSEC:0000950170-24-030314:0
2,450,000 shares@ US$1.6012.7% of flowCommon StockSEC:0001062993-23-019546:0
192,084 shares@ US$0.55212.3% of flowCommon StockSEC:0000950170-23-047530:0
5,437 shares@ US$0.552100.0% of flowCommon StockSEC:0000950170-23-047497:0
9,604 shares@ US$0.552100.0% of flowCommon StockSEC:0000950170-23-044379:0
9,604 shares@ US$0.552100.0% of flowCommon StockSEC:0000899243-23-016709:0
238,750 shares0Common StockSEC:0000899243-23-006742:0
100,000 shares@ US$7.502.5% of flowCommon StockSEC:0001062993-22-017733:0
Canonical exit: 7 Nov 2022 (T+90)
97,000 shares@ US$7.242.3% of flowCommon StockSEC:0001062993-22-017623:0
Canonical exit: 6 Nov 2022 (T+90)
141,000 shares@ US$6.953.3% of flowCommon StockSEC:0001062993-22-017559:0
Canonical exit: 3 Nov 2022 (T+90)
95,100 shares@ US$6.172.0% of flowCommon StockSEC:0001062993-22-017481:0
Canonical exit: 2 Nov 2022 (T+90)
25 of 38 declarations
About Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics, Inc. (ticker: ALDX) is a U.S.-based biotechnology company listed on the NASDAQ, with corporate headquarters in Lexington, Massachusetts, United States. The company traces its roots back to Aldexa Therapeutics and adopted the Aldeyra Therapeutics name in 2014. It operates as a clinical-stage biotech focused on discovering and developing innovative therapies for immune-mediated diseases. ([ir.aldeyra.com](https://ir.aldeyra.com/faqs?utm_source=openai))
Aldeyra’s core scientific thesis is its proprietary RASP platform, which targets reactive aldehyde species, a family of endogenous molecules associated with inflammation and disease biology. Rather than relying on a conventional single-protein approach, the platform is designed to influence multiple inflammatory pathways. This gives Aldeyra a differentiated positioning among small-cap biotechs, although the investment case remains highly dependent on clinical validation and regulatory outcomes. ([aldeyra.com](https://www.aldeyra.com/about/?utm_source=openai))
Read moreShow less
The company’s lead asset is reproxalap, an investigational ophthalmic solution being developed for the signs and symptoms of dry eye disease. The program has been central to the equity story and has also been a source of volatility: the FDA accepted the NDA at one point, issued a Complete Response Letter in April 2025, and Aldeyra subsequently resubmitted the application in June 2025. In May 2025, the company also reported achievement of the primary endpoint in a Phase 3 dry eye chamber trial. Later regulatory updates confirmed that the FDA accepted the resubmission for review and assigned a new PDUFA target action date. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1341235/000121390025064869/ea0249257-8k_aldeyra.htm?utm_source=openai))
Beyond reproxalap, Aldeyra is advancing additional RASP modulators, including ADX-629, an oral candidate studied in systemic inflammatory conditions, and other early-stage programs. In 2025, the company also highlighted an expansion of the RASP platform into central nervous system diseases, signaling an attempt to broaden the pipeline beyond ophthalmology and into additional inflammatory or immune-linked indications. ([ir.aldeyra.com](https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-advances-investigational-oral-rasp?utm_source=openai))
From a competitive standpoint, Aldeyra operates in a crowded biotech landscape where larger pharmaceutical companies and better-capitalized peers dominate commercialization and late-stage development. Its potential edge lies in the novelty of the RASP mechanism and the possibility of creating first-in-class or best-in-class assets. However, the company remains a development-stage organization with meaningful exposure to clinical trial readouts, FDA decisions, financing needs, and future commercialization execution. ([aldeyra.com](https://www.aldeyra.com/science-technology/?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
